Article

Immunotherapy: an emerging strategies against prostate castration resistant cancer.

CHU Jean-Minjoz, oncologie médicale, boulevard Flemming, 25000 Besançon, France.
Bulletin du cancer (impact factor: 0.67). 04/2012; DOI:10.1684/bdc.2012.1564
Source: PubMed

ABSTRACT Castration resistant prostate cancer occurs when patients experience disease progression despite appropriate hormonal manipulations. In these patients, chemotherapy remains standard treatment. Preclinical and clinical data have demonstrated the potential utility of an immunotherapy-based approach for the treatment of prostate cancer (PC). The phase III trial (IMPACT) has recently reported an advantage for Sipuleucel-T over placebo, with an overall survival 4.1 months superior to placebo. Sipuleucel-T is also the first FDA-approved immunotherapy for prostate cancer. These promising results need to be confirmed with other large studies and within previous step of PC. Neoplasic cells can escape immune responses by multiple mechanisms. A better knowledge of these mechanisms is of major concern for the future development of new immunotherapies approach.

0 0
 · 
0 Bookmarks
 · 
49 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

appropriate hormonal manipulations
 
Castration resistant prostate cancer
 
clinical data
 
first FDA-approved immunotherapy
 
future development
 
immune responses
 
large studies
 
major concern
 
multiple mechanisms
 
Neoplasic cells
 
new immunotherapies approach
 
phase III trial
 
Preclinical
 
promising results
 
Sipuleucel-T
 
standard treatment
 
survival 4.1 months superior